Taken together, recent studies make a powerful case for the licensing of aromatase inhibitors in the adjuvant setting, offering an alternative to tamoxifen which has long been the gold standard in breast cancer therapy in the prevention of recurrence.
|Number of pages||6|
|Publication status||Published - Dec 2004|
- Antineoplastic Agents, Hormonal
- Breast Neoplasms
- Chemotherapy, Adjuvant
- Treatment Outcome